Shinn Capital Group, Inc. Files Suit in Colorado Against Several Institutions, Including Dr. Leland Shapiro, to Obtain Favorable Test Results for Tubercin, an Anti-Cancer and HIV/AIDS Immunostimulant.
  Tuesday October 11, 9:24 pm ET
  SACRAMENTO, Calif.--(BUSINESS WIRE)--Oct. 11, 2005--Dr. Ronald Shinn, President and CEO of Artec, Inc. (Pink Sheets:ATKJ - News) announced today that Shinn Capital Group, Inc. has filed a friendly suit in Colorado. The suit is against the Denver Research Institute, the University of Colorado Health Sciences Center, the Denver Veteran's Affairs Medical Center and Dr. Leland Shapiro to obtain all Tubercin samples, test reports, studies, lab notes, protocols, statistical data, opinions and conclusions regarding studies relating to Tubercin.    "We believe that the Colorado test results are favorable regarding Tubercin's ability to combat both Cancer and AIDS as an Immunostimulant. Because Shinn Capital Group, Inc. is the lawful owner of Tubercin, it is entitled to these test results and has instituted a friendly lawsuit in Colorado to seek the same," states Dr. Shinn. 
  In addition, Shinn Capital Group, Inc. has moved the Court in Oklahoma to sanction both Colm J. King and Hard to Treat Diseases, Inc., a Florida corporation, for concealment or removal of Tubercin subject to the Court's Order of Delivery. The motion notes that Colm J. King's actions might constitute a misdemeanor subjecting him to a fine and imprisonment for a term of six (6) months, and seeks an Order that both Colm J. King and Hard to Treat Diseases, Inc. shall be liable to Shinn Capital Group, Inc. for double the amount of damage done to the property together with reasonable attorney's fees. 
  "We will continue to provide updates on our progress," states Gerry Knight. Artec holds a sub-license agreement for the United States and Canada for the development and marketing of Tubercin from Shinn Capital Group, Inc. You can view our web site at artec-inc.net. 
  Contact:       Artec, Inc.      Gerry Knight, 800-388-8875 or 405-949-1808
  Source: Shinn Capital Group
  biz.yahoo.com |